Peter Palese, PhD
img_Peter Palese
PROFESSOR & CHAIR | Microbiology
PROFESSOR | Medicine, Infectious Diseases
Research Topics
Antivirals, Apoptosis/Cell Death, Biodefense, Coronavirus, Influenza Virus, Interferon, Interferon Antagonists, Nipah Virus, Paramyxovirus, RNA, SARS Virus, Vaccine Development, Virulence Genes, Viruses and Virology
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Microbiology [MIC]
The Palese Laboratory focuses on fundamental questions concerning the genetic make-up and biology of viruses, as well as virus-host interactions.  They use molecular biological techniques to understand how viruses replicate and how they interact with cells to cause disease in their hosts.  Emphasis is on the study of RNA viruses, including influenza, paramyxo, and corona viruses.  These are four major research directions in the laboratory at the present time:  (1) by genetically changing influenza viruses via recombinant DNA techniques, they are studying viral genes and gene products to develop a universal influenza virus vaccine; (2) intracellular proteins are identified that interact with viral proteins, and the biological functions of these cellular proteins are studies; (3) attempts are made to develop broad spectrum antivirals and to identify their mechanisms of actions.  

The Palese Laboratory is interested in training students and postdoctoral fellows who will become independent investigators in "molecular" studies of infectious viral diseases.

PhD, University of Vienna


Beijerinck Virology Prize

Royal Netherlands Academy of Arts and Sciences


Elected Fellow of the American Academy of Arts and Sciences


Honorary Doctorate

Baylor College of Medicine


Sanofi–Institut Pasteur Award


Election to the Institute of Medicine of the National Academy of Sciences


European Virology Award (EVA)

European Society for Virology


Elected Member

The German Academy of Sciences Leopoldina


Robert Koch Prize



Corresponding Member

Austrian Academy of Sciences



National Academy of Sciences


Selected Publications

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Alicia T. Widge, Amelia R. Hofstetter, Katherine V. Houser, Seemal F. Awan, Grace L. Chen, Maria C.Burgos Florez, Nina M. Berkowitz, Floreliz Mendoza, Cynthia S. Hendel, A. Holman LaSonji, Ingelise J. Gordon, Preeti Apte, C. Jason Liang, Martin R. Gaudinski, Emily E. Coates, Larisa Strom, Diane Wycuff, Sandra Vazquez, Judy A. Stein, Jason G. Gall, William C. Adams, Kevin Carlton, Rebecca A. Gillespie, Adrian Creanga, Michelle C. Crank, Sarah F. Andrews, Mike Castro, Leonid A. Serebryannyy, Sandeep R. Narpala, Christian Hatcher, Bob C. Lin, Sarah O'Connell, Alec W. Freyn, Victoria C. Rosado, Raffael Nachbagauer, Peter Palese, Masaru Kanekiyo, Adrian B. McDermott, Richard A. Koup, Lesia K. Dropulic, Barney S. Graham, John R. Mascola, Julie E. Ledgerwood, Allison Beck, Joseph Casazza, Christopher L. Case, John Misasi, Abidemi O. Ola, Karen Parker, Richard Wu. Science Translational Medicine

Influenza virus. Frederick G. Hayden, Peter Palese.

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Katherine V. Houser, Grace L. Chen, Cristina Carter, Michelle C. Crank, Thuy A. Nguyen, Maria Claudia Burgos Florez, Nina M. Berkowitz, Floreliz Mendoza, Cynthia Starr Hendel, Ingelise J. Gordon, Emily E. Coates, Sandra Vazquez, Judy Stein, Christopher L. Case, Heather Lawlor, Kevin Carlton, Martin R. Gaudinski, Larisa Strom, Amelia R. Hofstetter, C. Jason Liang, Sandeep Narpala, Christian Hatcher, Rebecca A. Gillespie, Adrian Creanga, Masaru Kanekiyo, Julie E. Raab, Sarah F. Andrews, Yi Zhang, Eun Sung Yang, Lingshu Wang, Kwanyee Leung, Wing Pui Kong, Alec W. Freyn, Raffael Nachbagauer, Peter Palese, Robert T. Bailer, Adrian B. McDermott, Richard A. Koup, Jason G. Gall, Frank Arnold, John R. Mascola, Barney S. Graham, Julie E. Ledgerwood, Joseph Casazza, Lasonji Holman, Abidemi O. Ola, Pamela Costner, Jennifer Cunningham, Brenda Larkin, Laura Novik. Nature Medicine

View All Publications

Peter Palese, PhD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Palese during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Company Founder:

  • Vaxalto


  • Accurius
  • Vaxalto
  • Avimex
  • Boehringer Ingelheim Corporation
  • Opentrons Lab Works
  • Anvateo Biosciences London
  • Novavax
  • Revelar

Royalty Payments:

  • Avimex
  • MedImmune, LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.